Growth Differentiation Factor 15 (GDF15)-mediated HER2 Phosphorylation Reduces Trastuzumab Sensitivity of HER2-overexpressing Breast Cancer Cells

Overview

Journal Biochem Pharmacol

Specialties Biochemistry
Pharmacology

Date 2011 Aug 2

PMID 21803025

Citations 39

Authors

Jayashree P Joshi

Nicole E Brown

Samantha E Griner

Rita Nahta

Affiliations

Soon will be listed here.

Abstract

Resistance to the anti-HER2 monoclonal antibody trastuzumab is a major problem in the treatment of HER2-overexpressing metastatic breast cancer. Growth differentiation factor 15 (GDF15), which is structurally similar to TGF beta, has been reported to stimulate phosphorylation of HER2. We tested the hypothesis that GDF15-mediated phosphorylation of HER2 reduces the sensitivity of HER2-overexpressing breast cancer cell lines to trastuzumab. Gene microarray analysis, real-time PCR, and ELISA were used to assess GDF15 expression. Growth inhibition and proliferation assays in response to pharmacologic inhibitors of HER2, TGF beta receptor, or Src were performed on cells stimulated with recombinant human GDF15 or stable GDF15 transfectants. Western blotting was performed to determine effects of GDF15 on HER2 signaling. Cells were infected with lentiviral GDF15 shRNA plasmid to determine effects of GDF15 knockdown on cell survival in response to trastuzumab. Cells with acquired or primary trastuzumab resistance showed increased GDF15 expression. Exposure of trastuzumab-sensitive cells to recombinant human GDF15 or stable transfection of a GDF15 expression plasmid inhibited trastuzumab-mediated growth inhibition. HER2 tyrosine kinase inhibition abrogated GDF15-mediated Akt and Erk1/2 phosphorylation and blocked GDF15-mediated trastuzumab resistance. Pharmacologic inhibition of TGF beta receptor blocked GDF15-mediated phosphorylation of Src. Further, TGF beta receptor inhibition or Src inhibition blocked GDF15-mediated trastuzumab resistance. Finally, lentiviral GDF15 shRNA increased trastuzumab sensitivity in cells with acquired or primary trastuzumab resistance. These results support GDF15-mediated activation of TGF beta receptor-Src-HER2 signaling crosstalk as a novel mechanism of trastuzumab resistance.

Citing Articles

KLF4 suppresses the proliferation of perihilar cholangiocarcinoma by negatively regulating GDF15 and phosphorylating AKT.

Zhang X, Wang W, Lu C, Zhang H Oncol Rep. 2023; 50(6).

PMID: 37937607 PMC: 10652240. DOI: 10.3892/or.2023.8659.

Dysregulated Signalling Pathways Driving Anticancer Drug Resistance.

Bou Antoun N, Chioni A Int J Mol Sci. 2023; 24(15).

PMID: 37569598 PMC: 10418675. DOI: 10.3390/ijms241512222.

Mammaglobin 1 mediates progression of trastuzumab-resistant breast cancer cells through regulation of cyclins and NF-κB.

Kusumastuti R, Kumagai Y, Ishihara S, Enomoto A, Murakami T, Yasuda M FEBS Open Bio. 2022; 12(10):1797-1813.

PMID: 35945910 PMC: 9527592. DOI: 10.1002/2211-5463.13468.

M1 Macrophages Enhance Survival and Invasion of Oral Squamous Cell Carcinoma by Inducing GDF15-Mediated ErbB2 Phosphorylation.

Lv C, Li S, Zhao J, Yang P, Yang C ACS Omega. 2022; 7(13):11405-11414.

PMID: 35415372 PMC: 8992263. DOI: 10.1021/acsomega.2c00571.

Macrophage inhibitory cytokine-1 in cancer: Beyond the cellular phenotype.

Muniyan S, Pothuraju R, Seshacharyulu P, Batra S Cancer Lett. 2022; 536:215664.

PMID: 35351601 PMC: 9088220. DOI: 10.1016/j.canlet.2022.215664.

References

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Staff A, Bock A, Becker C, Kempf T, Wollert K, Davidson B . Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol. 2010; 118(3):237-43. DOI: 10.1016/j.ygyno.2010.05.032. View

Ozbay T, Durden D, Liu T, ORegan R, Nahta R . In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother Pharmacol. 2009; 65(4):697-706. PMC: 2808522. DOI: 10.1007/s00280-009-1075-9. View

Bottner M, Laaff M, Schechinger B, Rappold G, Unsicker K, Suter-Crazzolara C . Characterization of the rat, mouse, and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1). Gene. 1999; 237(1):105-11. DOI: 10.1016/s0378-1119(99)00309-1. View

Baek S, Kim J, Nixon J, DiAugustine R, Eling T . Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem. 2003; 279(8):6883-92. DOI: 10.1074/jbc.M305295200. View

Gu L, Waliany S, Kane S . Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance. PLoS One. 2009; 4(7):e6220. PMC: 2704867. DOI: 10.1371/journal.pone.0006220. View

Yamaguchi K, Lee S, Eling T, Baek S . Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway. J Biol Chem. 2004; 279(48):49617-23. DOI: 10.1074/jbc.M408796200. View

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H . Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol. 2009; 21(2):255-262. DOI: 10.1093/annonc/mdp304. View

10.

Chen Y, Lin P, Chen S, Lin C, Tsai N, Cheng Y . Activation of nonsteroidal anti-inflammatory drug-activated gene-1 via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase revealed a isochaihulactone-triggered apoptotic pathway in human lung cancer A549 cells. J Pharmacol Exp Ther. 2007; 323(2):746-56. DOI: 10.1124/jpet.107.126193. View

11.

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz C, Dantis L . Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996; 14(3):737-44. DOI: 10.1200/JCO.1996.14.3.737. View

12.

Park Y, Lee H, Lee J . Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells. BMB Rep. 2010; 43(2):91-6. DOI: 10.5483/bmbrep.2010.43.2.091. View

13.

Nahta R, Yuan L, Zhang B, Kobayashi R, Esteva F . Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005; 65(23):11118-28. DOI: 10.1158/0008-5472.CAN-04-3841. View

14.

Berns K, Horlings H, Hennessy B, Madiredjo M, Hijmans E, Beelen K . A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007; 12(4):395-402. DOI: 10.1016/j.ccr.2007.08.030. View

15.

Nahta R, Takahashi T, Ueno N, Hung M, Esteva F . P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004; 64(11):3981-6. DOI: 10.1158/0008-5472.CAN-03-3900. View

16.

Brown D, Ward R, Buckhaults P, Liu T, Romans K, Hawkins N . MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res. 2003; 9(7):2642-50. View

17.

Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit S . GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res. 2010; 16(15):3851-9. DOI: 10.1158/1078-0432.CCR-10-0705. View

18.

Osada M, Park H, Park M, Liu J, Wu G, Trink B . A p53-type response element in the GDF15 promoter confers high specificity for p53 activation. Biochem Biophys Res Commun. 2007; 354(4):913-8. PMC: 1975780. DOI: 10.1016/j.bbrc.2007.01.089. View

19.

Rowe D, Ozbay T, Bender L, Nahta R . Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Mol Cancer Ther. 2008; 7(7):1900-8. PMC: 2586607. DOI: 10.1158/1535-7163.MCT-08-0012. View

20.

Bootcov M, Bauskin A, Valenzuela S, Moore A, Bansal M, He X . MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997; 94(21):11514-9. PMC: 23523. DOI: 10.1073/pnas.94.21.11514. View